Serapha Bio just launched with $230 million and a gene-editing therapy licensed from a Chinese biotech, drawing checks from RA Capital, RTW, and a who's who of specialist funds. It's the biggest gene-editing Series A of the year, and it's wading straight into the deep end of U.S.-China biotech politics.
The Biggest Gene-Editing Debut Nobody Saw Coming
Most biotech startups launch with a press release, a PowerPoint, and a prayer. Serapha Bio launched with $230 million and one of the most politically complicated drug deals of the year.
The company burst onto the scene last week with a massive Series A financing built around a single asset: an in vivo base-editing therapy licensed from a Chinese biotech called YolTech Therapeutics. The goal is a one-shot genetic fix for a rare but serious lung and liver disease. The backdrop? A Washington establishment that's increasingly suspicious of anything with "China" and "biotech" in the same sentence.
And yet, some of the smartest money in biotech wrote enormous checks anyway.
What Serapha Actually Does
Serapha's lead program, SERP-01, targets alpha-1 antitrypsin deficiency (AATD), a genetic condition where a single mutation in the SERPINA1 gene causes the liver to produce a misfolded protein. Think of it like a factory that keeps churning out defective parts: the bad protein clogs up the liver while failing to protect the lungs. Over time, patients develop emphysema, liver disease, or both.
The current standard of care is augmentation therapy, essentially giving patients weekly infusions of the correct protein harvested from donated blood plasma. It's expensive, it's lifelong, and it doesn't fix the underlying problem.
Serapha's pitch is fundamentally different. SERP-01 uses base editing, a precision version of CRISPR gene editing that swaps a single DNA letter without cutting the entire double strand. If it works as intended, one treatment could correct the mutation at its source and restore normal protein production. One and done, no more infusions.
YolTech developed the therapy (known as YOLT-202 in China) and has already been enrolling patients in an investigator-initiated trial at Renji Hospital in Shanghai. That means Serapha isn't starting from zero; it's licensing a program with real human data behind it.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Follow the Money
The $230 million financing isn't a straightforward Series A. It's actually a two-part deal tied to a reverse merger with Boundless Bio, a struggling NASDAQ-listed company.
Of the total, $138 million has already been funded as a traditional Series A. The remaining $92 million is expected to close when the merger wraps up. After the dust settles, Serapha's investors will own roughly 96.3% of the combined public company. Boundless Bio shareholders? They'll hold about 3.7%, which tells you everything about who's really running the show.
The reverse merger playbook is increasingly popular in biotech right now. Instead of braving a shaky IPO market, you find a public shell, stuff your company inside it, and skip straight to a NASDAQ listing. It's the biotech equivalent of cutting the airport security line.
The deal gives Serapha a public-market platform and, crucially, enough cash to fund operations into the second half of 2029. That's enough runway to complete Phase 2 testing and start Phase 3 for SERP-01.
The Investor List Reads Like a Who's Who
This wasn't a round filled by unknown family offices. The financing was co-led by RA Capital Management and RTW Investments, two of the most respected specialist biotech funds in the world. The supporting cast includes Janus Henderson, Casdin Capital, Vivo Capital, Decheng Capital, Balyasny Asset Management, and several others.
When RA Capital and RTW both lead a deal, biotech investors pay attention. These aren't passive check-writers; they actively build companies. RA Capital's Rajeev Shah described SERP-01's clinical profile as "highly differentiated" and noted that RA will deploy its Blackbird clinical development accelerator to help Serapha move faster. RTW's Roderick Wong called SERP-01 a "potentially best-in-class base editing therapy" that could restore normal protein levels in the sickest patients.
To put the round in context: the average biotech Series A in 2025 and 2026 has been around $105 million. Serapha's $230 million is more than double that. Among gene-editing companies specifically, where typical Series A rounds land in the $50 to $100 million range, this financing is a clear outlier.
The China Question
This is where the story gets spicy. Serapha's core technology was born in China, developed by a Chinese company, and first tested in Chinese patients. In 2026, that raises eyebrows.
The BIOSECURE Act, signed into law in late 2025, restricts U.S. government agencies from working with certain Chinese biotech service companies designated through a framework based on the DoD 1260H list and OMB designations. Meanwhile, lawmakers recently introduced the BINSA (Biotech Investment National Security Act), which would subject cross-border biotech licensing deals to Treasury Department review. If passed, deals structured exactly like Serapha's could face new scrutiny.
But there's an important distinction that often gets lost in the headlines. The BIOSECURE Act targets service relationships, not intellectual property licensing. Hiring a designated Chinese manufacturer to make your drug for U.S. patients? That's a problem. Licensing a drug's IP rights from a Chinese developer? Currently, that's fine for private-sector companies.
Serapha's deal appears structured with this distinction firmly in mind. YolTech retains all rights in Greater China, receives an upfront cash payment, a minority equity stake in Serapha, over $2 billion in potential milestones, and tiered royalties on sales outside China. It's a clean territorial split designed to keep the U.S. and Chinese operations at arm's length.
The broader trend, despite all the geopolitical noise, is that China-to-U.S. biotech licensing is actually accelerating. Cross-border licensing deals from Chinese biotechs jumped 120% between 2022 and 2025 (from 42 to 93 deals), with aggregate upfront values rising roughly 400%. Chinese biotech assets accounted for about two-thirds of global licensing deal value in early 2026.
The deals are getting bigger, not smaller. They're just getting more carefully lawyered.
What Could Go Wrong
Plenty, honestly. Base editing is still a young technology, and long-term safety data (off-target edits, potential cancer risk) are years away from being fully understood. AATD is also attracting competition from other gene-therapy and gene-editing approaches, so "best-in-class" is a moving target.
Then there's the regulatory wild card. If BINSA passes and Treasury decides to review deals like this one, it could complicate Serapha's development timeline or force structural changes down the road.
And the leadership question remains oddly unresolved. As of launch, Serapha hasn't publicly named a CEO, chief medical officer, or chief scientific officer. The SEC filings confirm that Serapha will control the board and all executive appointments after the merger, but the actual names? Still a mystery. For a $230 million company, that's unusual.
The Bottom Line
Serapha Bio's launch is a fascinating test case for 2026 biotech. Can you build a blockbuster drug company around Chinese-origin science, navigate an increasingly hostile geopolitical environment, and keep some of the world's savviest investors on board?
With $230 million, a runway stretching into 2029, and a one-shot gene editor that could replace lifelong infusions, Serapha is betting the answer is yes. The next few years will tell us if they're right, or if the politics will catch up to the science.
Deals & M&A4 min read
Eli Lilly Just Spent $6.3 Billion to Fix a Problem You Didn't Know It Had
Eli Lilly is paying up to $7.8 billion for Centessa Pharmaceuticals and its experimental sleep disorder drugs. It's the biggest signal yet that the GLP-1 king is building a second empire, and the orexin agonist race just got a lot more interesting.
